Limits...
Prognostic Significance of Survivin Expression in Osteosarcoma Patients: A Meta-Analysis.

Liu Y, Teng Z, Wang Y, Gao P, Chen J - Med. Sci. Monit. (2015)

Bottom Line: No significant heterogeneity was observed among included studies (P>0.01, I2<50%).Our results show that survivin expression increased the 5-year overall survival (RR=0.48, 95% CI=0.32-0.71, P=0.0002) and rate of postoperative recurrence (RR=1.80, 95% CI=1.09-2.97, P=0.02).I-IIa: OR=5.26, 95% CI=3.76-7.34, P<0.00001; Price's grade, III vs.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedics, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China (mainland).

ABSTRACT

Background: Osteosarcoma is the most common primary bone malignancy and has poor prognosis. Survivin has been identified as an independent prognostic factor for a majority of cancers. In the present study, we evaluated the effect of survivin expression on the clinical outcome of osteosarcoma patients.

Material and methods: Online electronic databases were searched for related articles published between 2000 and 2015. Odds ratio (OR) and risk ratio (RR) with their 95% confidence intervals (CI) were employed to calculate the significance.

Results: Overall, a total of 20 relevant studies were selected, including 1030 patients. No significant heterogeneity was observed among included studies (P>0.01, I2<50%). Survivin was expressed in 68.6% of all cases. Our results show that survivin expression increased the 5-year overall survival (RR=0.48, 95% CI=0.32-0.71, P=0.0002) and rate of postoperative recurrence (RR=1.80, 95% CI=1.09-2.97, P=0.02). It was associated with the grade of osteosarcoma (Enneking clinical stage, IIb-III vs. I-IIa: OR=5.26, 95% CI=3.76-7.34, P<0.00001; Price's grade, III vs. I+II: OR=2.04, 95% CI=1.16-3.61, P=0.01), metastasis, and soft tissue invasion of osteosarcoma (OR=6.25, 95% CI=3.74-10.45, P<0.00001; OR=6.15, 95% CI=3.74-10.11, P<0.00001). No relationship was found between survivin expression and sex, age, or tumor size in patients with osteosarcoma.

Conclusions: Our results suggest that survivin can function as a new diagnostic biomarker for osteosarcoma and be used as a reference index to determine pathology classification of osteosarcoma, providing new targets for gene therapy of osteosarcoma.

No MeSH data available.


Related in: MedlinePlus

Funnel plot of survivin expression on Enneking clinical stage of osteosarcoma metastasis and soft tissue invasion, and postoperative recurrence in patients with osteosarcoma.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4588668&req=5

f6-medscimonit-21-2877: Funnel plot of survivin expression on Enneking clinical stage of osteosarcoma metastasis and soft tissue invasion, and postoperative recurrence in patients with osteosarcoma.

Mentions: Individual studies were deleted on at a time to verify the influence of each single study on the overall results in each comparison; our results showed that the pooled OR and RR were not significantly changed. The funnel plot was used to further evaluate publication bias among included studies. As shown in Figure 6, 1 dot represents 1 included study. The dot outside the funnel represents the study by He et al. When this study was omitted from our analysis, no obvious asymmetry presented, and the results remained unchanged. Moreover, the heterogeneity between studies was not significantly changed (Before: P=0.81, I2=0%; After: P=1.00, I2=0%). These results indicated that there was no publication bias.


Prognostic Significance of Survivin Expression in Osteosarcoma Patients: A Meta-Analysis.

Liu Y, Teng Z, Wang Y, Gao P, Chen J - Med. Sci. Monit. (2015)

Funnel plot of survivin expression on Enneking clinical stage of osteosarcoma metastasis and soft tissue invasion, and postoperative recurrence in patients with osteosarcoma.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4588668&req=5

f6-medscimonit-21-2877: Funnel plot of survivin expression on Enneking clinical stage of osteosarcoma metastasis and soft tissue invasion, and postoperative recurrence in patients with osteosarcoma.
Mentions: Individual studies were deleted on at a time to verify the influence of each single study on the overall results in each comparison; our results showed that the pooled OR and RR were not significantly changed. The funnel plot was used to further evaluate publication bias among included studies. As shown in Figure 6, 1 dot represents 1 included study. The dot outside the funnel represents the study by He et al. When this study was omitted from our analysis, no obvious asymmetry presented, and the results remained unchanged. Moreover, the heterogeneity between studies was not significantly changed (Before: P=0.81, I2=0%; After: P=1.00, I2=0%). These results indicated that there was no publication bias.

Bottom Line: No significant heterogeneity was observed among included studies (P>0.01, I2<50%).Our results show that survivin expression increased the 5-year overall survival (RR=0.48, 95% CI=0.32-0.71, P=0.0002) and rate of postoperative recurrence (RR=1.80, 95% CI=1.09-2.97, P=0.02).I-IIa: OR=5.26, 95% CI=3.76-7.34, P<0.00001; Price's grade, III vs.

View Article: PubMed Central - PubMed

Affiliation: Department of Orthopedics, Affiliated Hospital of Hebei University of Engineering, Handan, Hebei, China (mainland).

ABSTRACT

Background: Osteosarcoma is the most common primary bone malignancy and has poor prognosis. Survivin has been identified as an independent prognostic factor for a majority of cancers. In the present study, we evaluated the effect of survivin expression on the clinical outcome of osteosarcoma patients.

Material and methods: Online electronic databases were searched for related articles published between 2000 and 2015. Odds ratio (OR) and risk ratio (RR) with their 95% confidence intervals (CI) were employed to calculate the significance.

Results: Overall, a total of 20 relevant studies were selected, including 1030 patients. No significant heterogeneity was observed among included studies (P>0.01, I2<50%). Survivin was expressed in 68.6% of all cases. Our results show that survivin expression increased the 5-year overall survival (RR=0.48, 95% CI=0.32-0.71, P=0.0002) and rate of postoperative recurrence (RR=1.80, 95% CI=1.09-2.97, P=0.02). It was associated with the grade of osteosarcoma (Enneking clinical stage, IIb-III vs. I-IIa: OR=5.26, 95% CI=3.76-7.34, P<0.00001; Price's grade, III vs. I+II: OR=2.04, 95% CI=1.16-3.61, P=0.01), metastasis, and soft tissue invasion of osteosarcoma (OR=6.25, 95% CI=3.74-10.45, P<0.00001; OR=6.15, 95% CI=3.74-10.11, P<0.00001). No relationship was found between survivin expression and sex, age, or tumor size in patients with osteosarcoma.

Conclusions: Our results suggest that survivin can function as a new diagnostic biomarker for osteosarcoma and be used as a reference index to determine pathology classification of osteosarcoma, providing new targets for gene therapy of osteosarcoma.

No MeSH data available.


Related in: MedlinePlus